Date Title Description PDF
22 Feb 2022 On buy-back programmes ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022.     Download
16 Feb 2022 On business and financial situation Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years       Download
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download
22 Jun 2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Download

Pages

Date Title Description PDF
08 May 2025 On business and financial situation ROVI informs on the award of a grant in its favor to develop the R&D Project IPCEI - ROVI (LAISOLID) Download
04 Apr 2025 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the first quarter of 2025 Download
25 Feb 2025 Annual Financial Reports and Audit Reports The Company submits the 2024 Annual Financial Report  Download
25 Feb 2025 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2024 annual report regarding remuneration of the members of the Board of Directors Download
07 Jan 2025 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the fourth quarter of 2024 Download

Pages

Date Title Description PDF
05 Oct 2017 Contratos de liquidez y contrapartida Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. Download
03 Oct 2017 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted from 11 July to 30 September 2017   Download
07 Sep 2017 Otros sobre negocio y situación financiera The Company informs that commences the enoxaparin biosimilar marketing in Germany Download
26 Jul 2017 Información sobre resultados ROVI releases the presentation related to the 2017 first half results Download
26 Jul 2017 Información sobre resultados ROVI releases the presentation related to the 2017 first half results Download

Pages